[HTML][HTML] An emerging treatment alternative for anemia in chronic kidney disease patients: a review of daprodustat
KA Becker, JJ Jones - Advances in therapy, 2018 - Springer
KA Becker, JJ Jones
Advances in therapy, 2018•SpringerThis article reviews an emerging therapeutic agent, which is currently in phase III
development for the treatment of anemia secondary to chronic kidney disease, covering
promising phase II results, drug characteristics, and the current phase III trials, which, if
approved, may significantly impact the management of anemia in this patient population.
development for the treatment of anemia secondary to chronic kidney disease, covering
promising phase II results, drug characteristics, and the current phase III trials, which, if
approved, may significantly impact the management of anemia in this patient population.
Abstract
This article reviews an emerging therapeutic agent, which is currently in phase III development for the treatment of anemia secondary to chronic kidney disease, covering promising phase II results, drug characteristics, and the current phase III trials, which, if approved, may significantly impact the management of anemia in this patient population.
Springer